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ABSTRACT
Imatinib, a BCR-Abl inhibitor, is a successful front-line treat-
ment for chronic myelogenous leukemia (CML). Despite the
success of imatinib, multiple mechanisms of resistance re-
main a problem, including overexpression of Lyn kinase (Lyn)
and Bcl-2 family antiapoptotic proteins. Profiling micro-RNA
(miRNA) expression in a model of Lyn-mediated imatinib-
resistant CML (MYL-R) identified approximately 30 miRNAs
whose expression differed 2-fold compared with drug-
sensitive MYL cells. In particular, the expression of the miR181
family (a–d) was significantly reduced (11- to 25-fold) in
MYL-R cells. Incubation of MYL-R cells with a Lyn inhibitor
(dasatinib) or nucleofection with Lyn-targeting short interfering
RNA increased miR181b and miR181d expression. A similar
Lyn-dependent regulation of miR181b and miR181d was ob-
served in imatinib-resistant K562 CML cells. Sequence analysis
of potential targets for miR181 regulation predicted myeloid cell
leukemia-1 (Mcl-1), a Bcl-2 family member whose expression is
increased in MYL-R cells and drug-resistant leukemias. Inhibi-
tion of Lyn or rescue of miR181b expression reduced Mcl-1
expression in the MYL-R cells. To further investigate the mech-
anism of Mcl-1 repression by miR181, a luciferase reporter
construct incorporating the Mcl-1 3-untranslated region was
tested. Overexpression of miR181b reduced luciferase activity,
whereas these effects were ablated by the mutation of the seed
region of the miR181 target site. Finally, stimulation of Lyn
expression by 1,25-dihydroxyvitamin D3 treatment in HL-60
cells, a cell model of acute myelogenous leukemia, decreased
miR181b expression and increased Mcl-1 expression. In sum-
mary, our results suggest that Lyn-dependent regulation of
miR181 is a novel mechanism of regulating Mcl-1 expression
and cell survival.
Introduction
The discovery and application of the BCR-Abl inhibitor
imatinib has been a major hallmark in the development of
kinase inhibitors for cancer chemotherapy. However, despite
the success of imatinib for the treatment of chronic myelog-
enous leukemia (CML) and other cancers, multiple mecha-
nisms of imatinib resistance have been identified. These in-
clude BCR-Abl mutations that prevent imatinib binding (i.e.,
T315I) (Hochhaus et al., 2002; Yamamoto et al., 2004), BCR-
Abl overexpression (Hochhaus et al., 2002), and increased
expression and activity of Src family kinases (SFKs) or other
prosurvival proteins (Illmer et al., 2004; Li, 2008). Lyn ki-
nase (Lyn) has been implicated in imatinib resistance in both
CML cells and patient samples. Overexpression of Lyn, the
most abundant SFK in hematopoietic cells, may contribute to
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drug resistance through increased signal transducer and ac-
tivator of transcription 5 phosphorylation, Bcl-2 expression,
and other prosurvival responses (Donato et al., 2003; Dai et
al., 2004; Nam et al., 2007). Inhibition of Lyn with SFK
inhibitors reduced prosurvival signaling and reversed ima-
tinib resistance in CML cells (Ito et al., 2007; Nam et al.,
2007). Moreover, the dual-specificity BCR-Abl/SFK inhibi-
tors (i.e., dasatinib, sorafenib, nilotinib) effectively treat pa-
tients who are nonresponsive to imatinib therapy (Li, 2008;
Wu et al., 2008).
MicroRNAs (miRNAs) are small (22–24 nucleotides) non-
coding RNA molecules that are key regulators of protein
expression through their targeted binding to specific mRNAs.
By forming a double-stranded RNA duplex with target mRNAs
in the RNA-induced silencing complex, miRNAs trigger the
degradation of the mRNA transcript or directly inhibit protein
translation (Ambros, 2001). More than 700 miRNAs have been
described in humans, and patterns of deletion, down-regula-
tion, or up-regulation of specific miRNAs have been character-
ized in B-cell chronic lymphocytic leukemias, acute myeloge-
nous leukemia (AML), and CML (Calin et al., 2005; Venturini et
al., 2007; Dixon-McIver et al., 2008). Recent studies have dem-
onstrated the importance of miR181 (a–d) expression in AML
and chronic lymphocytic leukemia. MiR181a is involved in he-
matopoietic differentiation (Chen et al., 2004), and loss of
miR181 strongly correlates with a common AML morphological
subtype (Debernardi et al., 2007). Moreover, high miR181 (a–d)
expression is prognostic for the achievement of complete remis-
sion and event-free survival in patients with AML (Marcucci et
al., 2008; Schwind et al., 2009).
Bcl-2 family members are important prosurvival regula-
tors of apoptosis that have been implicated in the promotion
of drug resistance in cell models of leukemia (Shangary and
Johnson, 2003; Dai et al., 2004; Bagrintseva et al., 2005).
Myeloid cell leukemia-1 (Mcl-1) is a Bcl-2 family protein
shown to correlate with leukemic relapse in AML and has
been directly linked to resistance to chemotherapy (Kauf-
mann et al., 1998). In addition, Mcl-1 was recently implicated
in AML survival in response to FLT-3 internal tandem du-
plications, a common mechanism of resistance in AML that
involves the activation of Lyn (Okamoto et al., 2007; Breiten-
buecher et al., 2009). Mcl-1 functions at the mitochondria by
sequestering the proapoptotic BH3-only proteins Bim and
Noxa, thereby preventing cytochrome c release and cell death
(Warr and Shore, 2008). Mechanisms to inhibit Mcl-1 func-
tion include ubiquitination and degradation directed by the
MULE/LASU1 E3-ligase (Zhong et al., 2005), and targeting
of Mcl-1 mRNA for degradation by miRNA has been de-
scribed previously (Mott et al., 2007; Chen et al., 2009; Craw-
ford et al., 2009).
In this study, we describe a novel mechanism by which Lyn
may confer multidrug resistance in a cell model of CML by
repressing the expression of miR181. As our data show,
miR181b directly represses Mcl-1 expression, and the Lyn-
dependent loss of miR181 results in enhanced Mcl-1 levels
and increased drug resistance. Thus, this is the first demon-
stration, to our knowledge, of Mcl-1 as a bona fide target of
miR181 and suggests that the regulation of miR181 by Lyn in
drug-resistant cells may contribute to this important anti-
apoptotic mechanism.
Materials and Methods
Cell Culture and Reagents. MYL and MYL-R human CML cells
were a generous gift from Dr. Hideo Tanaka (Department of Hema-
tology and Oncology, Hiroshima University, Hiroshima, Japan).
K562-R cells were obtained from Dr. Steven Grant [Massey Cancer
Center, Virginia Commonwealth University, Richmond, VA; K562-
R(1)]. A separate isolate of imatinib-resistant K562 cells was kindly
provided by Dr. Nicholas Donato [Department of Internal Medicine,
University of Michigan; K562-R(2)]. HL-60 cells were obtained from
the University of North Carolina Tissue Culture Facility (Chapel
Hill, NC). Cells were cultured in RPMI 1640 medium (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Norcross, GA) and 1% antibiotic/antimycotic (Invitro-
gen). The imatinib-resistant cells (MYL-R, K562R) were not contin-
uously cultured in the presence of imatinib; however, imatinib resis-
tance and Lyn overexpression was routinely checked and found to be
stably maintained. HEK293T cells were a generous gift from Dr.
Channing Der (Department of Pharmacology, University of North
Carolina, Chapel Hill, NC) and were maintained in Dulbecco’s mod-
ified Eagle’s medium (Invitrogen) supplemented with 10% fetal bo-
vine serum and 1% antibiotic/antimycotic. Cell cultures were main-
tained and incubated with drug at 37°C in a 5% CO2 humidified
atmosphere. Imatinib and dasatinib were purchased from LC Labo-
ratories (Woburn, MA). SMARTpool siRNA was purchased from
Thermo Fisher Scientific (Waltham, MA). 1,25-Dihydroxyvitamin D3
(1,25-D3) was purchased from Enzo Life Sciences International (Ply-
mouth Meeting, PA).
Nucleofection. Plasmids and siRNA were incorporated into cells
using a nucleofection system (Amaxa Biosystems, Gaithersburg,
MD; 90% transfection efficiency with 90% cell viability; data not
shown). In brief, 1.0 to 1.5  106 cells were washed with phosphate-
buffered saline and resuspended in nucleofection solution (Mirus Bio
LLC, Madison, WI). Cells were nucleofected using the T-16 nucleo-
fector program and added to 4.5 ml of nutrient-rich media. Cells were
cultured in a 5% CO2 humidified atmosphere at 37°C for 24 h before
experimentation.
Plasmid Constructs and Site-Directed Mutagenesis. The
mature human miR181b sequence was cloned into the SDSA 3.0
expression plasmid using the BglII and Xho1 restriction sites. After
incorporation into cells, this plasmid expresses miR181b concomi-
tantly with GFP. The Mcl-1 3-UTR luciferase expression construct
was a generous gift from Dr. Serge Nana-Sinkam (Division of Pul-
monary, Allergy, Critical Care and Sleep Medicine, Ohio State Uni-
versity, Columbus, OH). This is a psicheck-2 plasmid vector that
incorporates the 3-UTR of Mcl-1 downstream of the luciferase gene
(Crawford et al., 2009). Site-directed mutagenesis of the miR181b
binding site was performed using the following primers: forward,
5-CCATTTAAAAATAGGTATGAATAAGATGACTAAGATACTAAT-
GGGGAAGAACTGCCCTG-3; and reverse, 5-CAGGGCAGTTCT-
TCCCCATTAGTATCTTAGTCATCTTATTCATACCTATTTTTAAAT
GG-3. The reaction mix included 1-ng template DNA, dNTPs, and
forward and reverse primers. Touchdown PCR was performed on a
Thermocycler (Eppendorf North America, New York, NY); after an
initial incubation at 95°C for 2 min, the following steps were cycled
18 times: 95°C for 50 s, 70355°C (each cycle was performed with a
temperature 1° lower) for 50 s, and 72°C for 14 min. The PCR product
was treated with Dpn1, and DH5 Escherichia coli (Invitrogen) were
transformed according to the manufacturer’s instructions. Mutation
was confirmed by sequencing (Genome Analysis Facility, University
of North Carolina, Chapel Hill, NC).
Caspase-3 Activity Assay. To determine caspase-3 activity, cells
(6  104/well) were incubated with drug or vehicle in a 96-well plate.
Plates were then centrifuged for 5 min to pellet the cells. Cells were
lysed on ice with buffer containing 250 mM HEPES, pH 7.4, 25 mM
CHAPS, and 25 mM dithiothreitol. The nonionic detergent disrupts
the plasma membrane and releases the cytosolic proteins without
denaturing the caspase protein. The activity of caspase-3 in these
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samples was determined using the Caspase-3 Fluorimetric Assay Kit
(Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s in-
structions. Fluorescence was measured using a FLUOstar Galaxy
plate reader (BMG Labtech, Durham, NC) with a 360-nm excitation
filter and a 460-nm emission filter.
qRT-PCR-Based miRNA Expression Profiling. Total RNA
was extracted from 40.0  106 MYL and MYL-R cells using TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions.
miRNA enrichment was then performed using the Small RNA Iso-
lation Kit (SABiosciences, Frederick, MD), and the miRNA purity
was assessed using an Agilent Bioanalyzer Chip (Genomics and
Bioinformatics Core, University of North Carolina, Chapel Hill, MD).
Finally, 100-ng miRNA was 3-polyadenylated and converted to
cDNA using the First-Stand Synthesis Kit (SABiosciences) according
to the manufacturer’s instructions.
Approximately 100-ng cDNA was added to the Human Cancer RT2
miRNA qPCR Array (SABiosciences; 1.0 ng/well), and qRT-PCR
was performed on an ABI 7500 Fast Real-Time Thermocycler (Ap-
plied Biosystems, Foster City, CA) according to the manufacturer’s
instructions. Melting-curve analysis of the resulting transcript was
determined. Analysis of the qRT-PCR data were performed using the
RT2 miRNA PCR Array Data Analysis program (available at http://
www.sabiosciences.com/pcr/arrayanalysis.php).
qRT-PCR Analysis of miR181 Expression. MiRNA 181 expres-
sion was measured using the Taqman MicroRNA Assay (Applied
Biosystems; miR181b and miR181d) according to the manufacturer’s
instructions with slight modification. In brief, total RNA was ex-
tracted from cells using TRIzol reagent. One microgram of RNA was
added to the following reaction mix: RT buffer, 1 mM dNTPs, U6
small nuclear RNA RT primers (Applied Biosystems), and RT prim-
ers against miR181b. Twenty-five units of the Multiscribe RT en-
zyme (Applied Biosystems) was added, and the reverse-transcription
reaction was performed on a PCR thermocycler. Twenty-five nano-
grams of the resulting cDNA was added to a qPCR mix containing
the Taqman Fast Universal PCR Master Mix (Applied Biosystem)
and the PCR primer/probe reaction mix against either miR181b or
U6 small nuclear RNA. Quantitative PCR was performed on an ABI
7500 Real-Time System, and data were analyzed using the 7500 Fast
software (Applied Biosystems).
Western Blot Analysis. Cells were collected, washed twice with
phosphate-buffered saline, and lysed using radioimmunoprecipita-
tion assay buffer (without SDS; 150 mM NaCl, 9.1 mM Na2HPO4, 1.7
mM NaH2PO4, 1% NP-40, and 0.5% deoxycholic acid, pH 7.4) sup-
plemented with protease and phosphatase inhibitors (150 M
Na3VO4, 0.25 mM phenylmethylsulfonyl fluoride, 5 g/ml leupeptin,
and 10 nM microcystin). The lysate was centrifuged, and the protein
concentration was determined using Bradford reagent (Thermo
Fisher Scientific). Sample buffer (2: 0.5 M Tris, 20% glycerol, 10%
-mercaptoethanol, and 0.002 g/ml bromphenol blue, pH 6.8) was
added to an equal volume of total protein (30–50 g), and the sam-
ples were separated by SDS-polyacrylamide gel electrophoresis. Pro-
teins were transferred to a polyvinylidene difluoride membrane (Mil-
lipore Bioscience Research Reagents, Billerica, MA). Membranes
were blocked with 5% nonfat dry milk in Tris-buffered saline sup-
plemented with Tween 20 (TBST; 9.9 mM Tris-HCl, 150 mM NaCl,
and 0.1% Tween 20, pH 8.0) for 1 h at room temperature. Primary
antibodies against Lyn (Santa Cruz Biotechnology; Santa Cruz, CA),
Mcl-1 (Santa Cruz Biotechnology), GFP (Sigma), SFK pY416 (Cell
Signaling Technology, Danvers, MA), and SFK pY527 (Cell Signaling
Technology) were diluted in 1% bovine serum albumin/TBST and
applied to a membrane overnight at 4°C or for 1 h at room temper-
ature. After the primary antibody incubation, membranes were
washed three times for 5 min in TBST. Secondary antibodies (horse-
radish peroxidase-conjugated anti-mouse or anti-rabbit immuno-
globulin; Santa Cruz Biotechnology) diluted in 1% gelatin/TBST
were then applied to the membrane for 1 h at room temperature.
-Actin (Santa Cruz Biotechnology) or -tubulin (Sigma-Aldrich)
expression was measured as a loading control. Membranes were
developed using enhanced chemiluminescence (GE Healthcare,
Chalfont St. Giles, Buckinghamshire, UK) with exposure to autora-
diography film. Densitometry was performed using a FluorChem
FC2 imager (Cell Biosciences, Santa Clara, CA).
Transfection and Luciferase Activity Assay. HEK293T cells
(3  105/well) were plated in poly(L-lysine)-treated six-well plates.
The next day, cells were transfected using Lipofectamine (Invitro-
gen) according to the manufacturer’s instructions.
Twenty-four hours after transfection, cells were lysed at room
temperature with radioimmunoprecipitation assay buffer (without
SDS). The lysate was centrifuged for 10 min at 10,000 rpm. Ten-
microliter aliquots of each sample was applied to a 96-well plate, and
150 l of the luciferase assay reaction mix (25 mM glycyl glycine, 15
mM MgSO4, 15 mM KPO4, and 4 mM EGTA, pH 7.8) containing 0.1
mg/ml luciferin (Sigma) was added to each well. Luciferase activity
was measured on a Pherastar luminometer (BMG Labtech). Western
blot analysis of GFP was performed to ensure equivalent transfec-
tion, and -actin expression was determined as a loading control.
Statistics. Data were analyzed using analysis of variance and t
tests where appropriate using Prism 4 software (GraphPad Software
Inc., San Diego, CA).
Results
Lyn Kinase Overexpression in MYL-R Cells Confers
Drug Resistance. Previous studies have demonstrated that
Lyn is important for MYL-R survival (Ito et al., 2007). To
compare Lyn expression and activity, lysates of MYL and
MYL-R cells were Western-blotted with antibodies that rec-
ognize total Lyn, active Lyn [P-Y397 (P-Y416 Src)], or inac-
tive Lyn [P-Y507 (P-Y527 Src)]. As shown in Fig. 1A, the Lyn
B splice form (53 kDa) was significantly overexpressed and
phosphorylated on the activation loop (Tyr397), indicating
increased activity in MYL-R cells. Likewise, the Lyn A splice
form (56 kDa), although reduced in expression, was also more
highly phosphorylated on this residue in the MYL-R cells
(Fig. 1A). Loss of the inactivating Tyr507 phosphorylation
was observed only for Lyn B, suggesting the elevated activity
state of this kinase in MYL-R cells. It is noteworthy that the
increase of Lyn activity was confirmed in these cells using a
novel peptide-based fluorescent Lyn biosensor (Wang et al.,
2010a).
Lyn hyperactivation has been attributed to imatinib resis-
tance in MYL-R cells (Ito et al., 2007). In addition, incubation
of MYL-R cells with gemcitabine, Ara-C, or adaphostin failed
to activate caspase-3 in these cells, demonstrating that
MYL-R are highly antiapoptotic (E. I. Zimmerman and L. M.
Graves, unpublished results). To investigate the importance
of Lyn in cell survival, MYL-R cells were transfected with
Lyn-directed siRNA or nontargeting control siRNA and then
exposed to 1 M imatinib. This treatment resulted in a
partial knockdown of Lyn and a significant increase in
caspase 3 activation (Fig. 1, B and C). However, the magni-
tude of caspase activation was less than in MYL cells exposed
to the same dose of imatinib (data not shown); this may be
due to incomplete silencing of Lyn expression (Fig. 1B). In
addition, pretreatment with 5-(4-chlorophenyl)-7-(dimethyl-
ethyl)pyrazolo[3,4-d]pyrimidine (PP2), a Lyn and SFK inhib-
itor, significantly elevated caspase activity in MYL-R cells
treated with imatinib, an effect not observed after pre-
treatment with the inactive inhibitor analog,
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP3)
(data not shown).
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MiR181 Expression Is Reduced in MYL-R Cells.
MiRNAs are small (20–22 nucleotides) noncoding RNA
regulators of protein expression that have been implicated
in the progression and survival of numerous cancers (Ham-
mond, 2006). To identify miRNAs involved in antiapopto-
sis, MYL and MYL-R cells were profiled for miRNA expres-
sion using the Human Cancer RT2 miRNA qPCR Array (SA
Biosciences). This qRT-PCR-based assay analyzed the ex-
pression of 88 known human miRNAs associated previ-
ously with cancer. Duplicate experiments demonstrated
that 15 miRNAs had a 2-fold increase in expression in
MYL-R cells relative to MYL cells (Fig. 2A) and that 15
miRNAs showed a 2-fold decrease in relative expression
(Fig. 2B). It is noteworthy that we observed a strong down-
regulation of the miR181 family (a–d) of miRNAs in
MYL-R cells (Fig. 2, B and C). This family of miRNAs is
highly conserved (Fig. 2D), and loss of miR181 expression
is prognostic for aggressive AML (Marcucci et al., 2008;
Schwind et al., 2009). To confirm the array results, indi-
vidual qRT-PCR of miR181b and miR181d was performed;
the results of these analyses showed that the expression of
both miRNAs was reduced approximately 10-fold in
MYL-R cells (Supplemental Fig. 1).
Lyn Inhibition Increases miR181 Expression in
MYL-R Cells. To determine whether hyperactivation of Lyn
regulated miR181 expression in MYL-R cells, cells were
treated with dasatinib, and miRNA expression was deter-
mined by qRT-PCR. As shown in Fig. 3, dasatinib treatment
inhibited Lyn and increased miR181b expression in MYL-R
cells in a dose-dependent manner (Fig. 3, A and B). Dasatinib
(1 nM) treatment produced minimal effects on cell viability
(15–20% cell loss), as determined by 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt assay and cell proliferation (data
not shown). In addition, nucleofection of MYL-R cells with
Lyn-targeted siRNA significantly elevated miR181b ex-
pression compared with control siRNA-treated cells (Fig.
3C). K562-R cells are a model of imatinib-resistant CML,
and overexpression of Lyn has been attributed to the
mechanism of resistance in these cells (Donato et al., 2003;
Dai et al., 2004). To further determine whether Lyn regu-
lates miR181 expression, we tested two independently sub-
cloned imatinib-resistant K562-R cell lines, termed K562-
R(1) and K562-R(2). Similar to MYL-R cells, dasatinib
treatment of K562-R cells inhibited Lyn activity and in-
creased miR181b expression (Fig. 3E-G). In addition, da-
satinib treatment increased miR181d expression in each
imatinib-resistant cell line (Fig. 3, D–F). These data sug-
gest that hyperactivation of Lyn represses miR181 expres-
sion in imatinib-resistant CML.
Mcl-1 Is a Target of miR181b. To investigate the potential
significance of miR181 to cell survival, we sought to identify
protein targets for miR181. Public database bioinformatic
algorithms (available at http://www.targetscan.org) pre-
dict a binding site for miR181 on the 3-UTR of Mcl-1, a Bcl-2
family member and antiapoptotic protein (Fig. 4A) (Warr and
Shore, 2008). Mcl-1 expression inversely correlates with leu-
kemia chemosensitivity (Kaufmann et al., 1998), and West-
ern blot analysis determined that Mcl-1 expression was
Fig. 1. Lyn kinase confers imatinib resistance in MYL-R cells. A, 2  106
cells were lysed and Western-blotted using the indicated antibodies
(pY507, inhibitory phosphorylation site; pY397, autophosphorylation
site). -Actin expression was similarly measured as a loading control, and
densitometry was performed. Representative data are shown. B and
C, 1  106 MYL-R cells were nucleofected with siRNA against Lyn or
nontargeting control siRNA. B, 48 h later, cells were lysed, and Western
blot analysis was performed using antibodies against Lyn and -actin,
and densitometry was performed. Representative data are shown. C, cells
were plated (6  105/well) in a 96-well plate and treated with imatinib
(1.0 M) or DMSO for the indicated time. Cells were then lysed, and
caspase-3 activity was measured. Data represent the mean  S.E.M. of
triplicate samples.
Fig. 2. Loss of miR181 expression in MYL-R cells. A and B, miRNA
expression was profiled in MYL and MYL-R cells by qRT-PCR using the
SuperArray cancer array. The heat map depicts 15 miRNAs that had a
2-fold increase (A) or decrease (B) in expression in MYL-R cells com-
pared with MYL cells. Arrows denote miR181 family members. Data rep-
resent duplicate experiments performed with triplicate samples. C, the fold
change in miR181 expression in MYL-R cells in comparison to MYL cells.
D, alignment of human miR181 miRNAs (533) using ClustalW soft-
ware (http://www.ebi.ac.uk/Tools/clustalw2/index.html). An asterisk de-
notes a conserved nucleotide.
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higher in MYL-R cells (Fig. 4B). Inhibition of Lyn with da-
satinib decreased Mcl-1 expression in a dose-dependent man-
ner, demonstrating the importance of Lyn activity in regu-
lating Mcl-1 expression (Fig. 4C).
To determine whether miR181b regulated Mcl-1 expres-
sion, MYL-R cells were nucleofected with an miR181b-
expressing plasmid vector (SDSA-miR181b) or empty vec-
tor (SDSA 3.0) control. Expression of GFP confirmed
nucleofection and plasmid processing (Fig. 5A). In addi-
tion, qRT-PCR confirmed miR181b expression in these
experiments (data not shown). As shown in Fig. 5, overex-
pression of miR181b in MYL-R cells significantly de-
creased Mcl-1 expression in comparison to the empty vec-
tor control (Fig. 5A).
miRNAs regulate protein expression by binding to the 3-
UTR of target mRNA and initiate mRNA degradation or
inhibit translational processing (Ambros, 2001). To deter-
mine whether miR181-dependent inhibition of Mcl-1 expres-
sion was due to a direct interaction, HEK293T cells were
cotransfected with the miR181b construct or empty vector
and a luciferase-reporter construct containing the 3-UTR of
Mcl-1 mRNA (Fig. 5B). Using this approach, we observed
that overexpression of miR181b significantly inhibited lucif-
erase activity compared with the vector control cells (Fig.
5C). Because the miRNA “seed region” is critical for the
recognition of miRNA targets, complementary nucleotides
within this region were mutated in the 3-UTR of the Mcl-1
luciferase reporter (Fig. 5B). These mutations ablated the
miR181b-dependent repression of luciferase activity (Fig.
5C), whereas mutation of nucleotides outside the seed region
failed to affect this process (data not shown). These data
suggest that miR181b directly interacts with the 3-UTR of
Mcl-1 mRNA to inhibit Mcl-1 protein expression, and nucle-
otides within the seed region of this binding site are impor-
tant to mediate this effect.
Lyn Regulates miR181b and Mcl-1 Expression in
AML. The HL-60 cell line is a commonly used cell model for
the study of AML. It was shown previously that 1,25-D3
treatment increased the expression of Lyn in these cells
(Wang et al., 2000). To determine whether manipulation of
Lyn expression in HL-60 cells affected miR181b and Mcl-1
expression, we treated these cells with 1,25-D3 for up to 96 h.
A strong increase in active Lyn expression was observed by
Western blotting these samples. In agreement with our data
obtained with the MYL-R and K562R cells, the increase in
Lyn expression correlated with repression of miR181b and
increased Mcl-1 expression in a time-dependent manner
(Fig. 6, A and B). Thus, these results indicate that Lyn can
affect Mcl-1 expression through modulation of miR181b
expression in an AML cell line.
Fig. 3. Lyn kinase inhibits miR181 expression. A and
B, 2  106 MYL-R cells were treated for 24 h with the
indicated dose of dasatinib or DMSO. A, total RNA was
extracted from 1  106 cells, and miR181b expression was
measured. Data represent the mean  S.E.M. of triplicate
samples. B, 1  106 cells were lysed, and Western blot
analysis was performed using the indicated antibodies.
Representative data are shown. C, 1  106 MYL-R cells
were nucleofected with siRNA against Lyn or nontargeting
control siRNA. Forty-eight hours later, RNA was extracted,
and miR181b expression was determined. Data represent
the mean  S.E.M. of duplicate experiments performed
with triplicate samples (, p  0.0036). D to G, 2  106
cells were treated for 24 h with 1 nM dasatinib or DMSO.
D to F, total RNA was extracted from 1  106 MYL-R (D),
K562-R(1) (E), and K562-R(2) cells (F), and miR181b and
miR181d expression was measured. Data represent the
mean  S.E.M. of duplicate experiments performed with
triplicate samples. G, 1  106 cells were lysed, and Western
blot analysis was performed using the indicated antibodies.
Representative data are shown.
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Discussion
These studies describe three important findings: 1, that
the hyperactivation of Lyn suppresses the expression of
miR181; 2, that miR181b represses the expression of a key
antiapoptotic protein, Mcl-1; and 3, loss of miR181 upon Lyn
activation may represent a novel mechanism of drug resis-
tance in leukemia. This mechanism was observed in cell
models of CML and AML, and the specific role of Lyn was
confirmed by both dasatinib treatment and siRNA against
Lyn. Considerable evidence now supports the role of Lyn as a
“compensatory oncogene” in imatinib-resistant CML and spe-
cific subtypes of AML. Lyn is overexpressed in drug-resistant
cell lines and patient samples (Donato et al., 2003; Dai et al.,
2004; Wu et al., 2008) and activated in response to Flt3
activation or Flt3-internal tandem duplication mutation
(Okamoto et al., 2007). Using a model of Lyn-dependent
CML, we observed strong repression of the miR181 family of
miRNAs. Low miR181 expression has previously been asso-
ciated with poor prognosis in AML, whereas high miR181
(a–d) expression is prognostic for event-free survival in pa-
tients with AML (Marcucci et al., 2008; Schwind et al., 2009).
Although our studies primarily focused on miR181b, this
family of miRNAs is highly conserved. Previous studies sug-
gest Bcl-2 as a target for repression by miR181 microRNAs
(Neilson et al., 2007; Chen et al., 2010). Comparison of the
potential 3-UTR targeting sequence of Bcl-2 with that of
Mcl-1 demonstrates a remarkable homology between these
sequences, which includes conservation within the seed se-
quence. The seed sequence is a key region of complementary
necessary for the targeting of miRNAs (Wang et al., 2010b).
Our results demonstrated that mutation of the nucleotides
complementary to the miR181 seed sequence in the 3-UTR
of Mcl-1 ablated the effects of miR181b. Whether miR181
directly targets Bcl-2 has yet to be confirmed; however, this is
would establish the importance of the miR181 family in the
regulation of mitochondria-mediated apoptosis.
Previous studies have identified multiple miRNAs that
are altered in drug-resistant cancer, suggesting that some
miRNAs have tumor suppressive effects, whereas others
regulate cell survival (Hummel et al., 2010). A recent study
profiled miRNAs from patients with imatinib-resistant
CML who did not have BCR/Abl mutations (San José-
Enériz et al., 2009). These authors identified 19 miRNAs
that were differentially expressed between drug-resistant
patients and drug-responders. In agreement with their
results, we observed down-regulation of the expression of
miR183 and two members of the Let7 family (Let 7a,
Let7b). However, in contrast to studies reporting de-
creased miR10a expression in drug-resistant CML, we ob-
served increased miR10a expression in the MYL-R cells.
Many of the other miRNAs reported by San José-Enériz et
al. (2009) were either unchanged or not present on our
arrays.
Previous studies have identified miRNAs that target Mcl-1
(Mott et al., 2007; Chen et al., 2009; Crawford et al., 2009),
and we measured the expression of these miRNAs in our cell
lines; however, the expression of these miRNAs was not
implicated in the mediation of Mcl-1 regulation in MYL and
MYL-R cells, suggesting that they may contribute to Mcl-1
expression in a cell type-specific manner. In addition to the
miR181 family, we observed many unique differences
in miRNA expression between MYL and MYL-R cells (miR10a,
miR128a, miR132, miR150, miR155, miR183, miR196a,
miR212). It is possible that some of these miRNAs may play a
role in the mediation of drug resistance, and this will be a
focus of future research.
Chen et al. (2010) demonstrated that miR181a overexpres-
Fig. 4. Mcl-1, a predicted target of miR181, is overexpressed in MYL-R
cells. A, diagram of the predicted miR181 binding site in the Mcl-1
3-UTR (available at http://www.targetscan.org). B, 2  106 cells were
lysed, and Western blot analysis was performed with the indicated anti-
bodies. Samples were loaded in duplicate. Representative data are
shown. C, 2  106 MYL-R cells were treated for 24 h with the indicated
dose of dasatinib or DMSO. Cells were lysed, and Western blotted with
the indicated antibodies. Representative data are shown.
Fig. 5. miR181b inhibits Mcl-1 expression. A, 1  106 MYL-R cells were
nucleofected with the SDSA 3.0 miR181b vector or empty vector (SDSA
3.0). Forty-eight hours later, cells were lysed, and Western blot analysis
was performed with the indicated antibodies. Representative data are
shown. B, diagram of luciferase constructs containing the Mcl-1 3-UTR.
Alignment of miR181b with the WT and mutant Mcl-1 3-UTR sequences.
An asterisk denotes a nucleotide mutation in the predicted miR181b
binding site. C, HEK293T cells were cotransfected with the indicated
SDSA 3.0 and psicheck Mcl-1 3-UTR vectors. Twenty-four hours later,
cells were lysed, and luciferase activity was measured. Data represent
the mean  S.E.M. of duplicate experiments performed with triplicate
samples (, p  0.001). E, Western blot analysis was performed with
the indicated antibodies. Representative data are shown.
Fig. 6. Enhancement of Lyn expression in HL-60 cells decreases miR181b
expression and increases Mcl-1 expression. A and B, 1  106 HL-60 cells
were treated with 10 ng/l 1,25-D3 for the indicated time. A, total RNA
was extracted from cells, and miR181b expression was measured. Data
represent the mean  S.E.M. of triplicate samples. B, cells were lysed,
and Western blot analysis was performed using the indicated antibodies.
Representative data are shown.
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sion sensitized cells to radiation. Moreover, Studzinski and
colleagues have demonstrated that 1,25-D3 treatment of
HL-60 cells not only increases Lyn expression, but also de-
creases miR181 expression and increases Mcl-1 expression
(Wang and Studzinski, 1997; Wang et al., 2000, 2009). This
work was published independently over the course of a de-
cade. Our study is in agreement with their data, and, impor-
tantly, we believe our study provides further mechanistic
insight to these observations. Finally, Studzinski and col-
leagues determined that 1,25-D3 treatment decreases sensi-
tivity to drugs that induce apoptosis (Xu et al., 1993); this
observation is in agreement with our data, which suggest
that Lyn-dependent loss of miR181 may contribute to the
development of imatinib resistance.
Although the mechanism of Lyn repression of miR181 is
not known, miRNA expression can be regulated by both ge-
netic and epigenetic mechanisms. For instance, the role of
BCR-Abl in the silencing of miR328 in CML through a mito-
gen-activated protein kinase-dependent manner was shown
recently (Eiring et al., 2010). Furthermore, activating muta-
tions of the c-Kit kinase induce a MYC-dependent repression
of miR29b in AML (Liu et al., 2010). In addition to transcrip-
tion factor (CCAAT-enhancer-binding protein , Myc, etc.)-
dependent mechanisms, kinases may regulate miRNA ex-
pression through post-transcriptional events, such as that
observed with LIN28 (Newman et al., 2008; Khusial et al.,
2009). Future studies will aim to determine the mechanism
of Lyn-dependent effects on miR181 expression.
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